Aduro Biotech, Inc. (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $11.06, for a total transaction of $442,400.00. Following the completion of the sale, the insider now directly owns 132,093 shares of the company’s stock, valued at $1,460,948.58. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Stephen T. Isaacs also recently made the following trade(s):

  • On Tuesday, May 16th, Stephen T. Isaacs sold 16,673 shares of Aduro Biotech stock. The stock was sold at an average price of $10.00, for a total transaction of $166,730.00.
  • On Monday, May 15th, Stephen T. Isaacs sold 10,600 shares of Aduro Biotech stock. The stock was sold at an average price of $10.01, for a total transaction of $106,106.00.
  • On Tuesday, May 16th, Stephen T. Isaacs sold 27,273 shares of Aduro Biotech stock. The stock was sold at an average price of $10.01, for a total transaction of $273,002.73.

Aduro Biotech, Inc. (ADRO) traded up 9.17% during mid-day trading on Thursday, hitting $12.50. 834,846 shares of the company were exchanged. Aduro Biotech, Inc. has a 12-month low of $8.75 and a 12-month high of $16.43. The company has a 50 day moving average of $10.39 and a 200 day moving average of $10.69. The stock’s market cap is $873.91 million.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. The company had revenue of $3.77 million for the quarter, compared to analyst estimates of $3.74 million. Aduro Biotech had a negative net margin of 166.85% and a negative return on equity of 35.35%. On average, equities research analysts expect that Aduro Biotech, Inc. will post ($1.39) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Aduro Biotech, Inc. (ADRO) Insider Stephen T. Isaacs Sells 40,000 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/06/aduro-biotech-inc-adro-insider-stephen-t-isaacs-sells-40000-shares-2.html.

ADRO has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 price target for the company. Rodman & Renshaw initiated coverage on shares of Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 price target for the company. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Monday, March 27th. Finally, Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday. Seven investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $19.00.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its position in shares of Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock valued at $101,571,000 after buying an additional 791,770 shares during the period. Norges Bank acquired a new position in shares of Aduro Biotech during the fourth quarter valued at about $3,266,000. Goldman Sachs Group Inc. raised its position in shares of Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 181,734 shares during the period. Renaissance Technologies LLC raised its position in shares of Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock valued at $1,955,000 after buying an additional 160,800 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in shares of Aduro Biotech during the first quarter valued at about $853,000. 35.68% of the stock is currently owned by institutional investors.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.